|
3.1.1 Tabac - e-cigs
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.10 Dép., diag. & prono. - Poumon
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5. Traitements
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.2 Pharma
|
|
|
Infinity Closes Research Ops as Blood Cancer Drug Comes Up Short [Xconomy]
|
|
|
|
|
|
Duvelisib
is a member of a more recent wave of PI3 kinase drugs, meant to be more
targeted and safer than their predecessors. And despite the fact that
the drug was well behind other rivals, like idelalisib, AbbVie was
intrigued. AbbVie paid $275 million to grab rights to Infinity’s drug,
and attached another $530 million in milestones to the deal.
|
|
|
|
|
|
|
Infinity’s Difficult History [In the Pipeline]
|
|
|
|
|
|
Infinity
stayed unbought, but as that first paragaph shows, it’s been a rough
ride. I can’t think of a better illustration of how hard drug
development is, and how it is no respecter of good ideas, hard work, and
talent.
|
|
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
Pharma’s secret weapon to keep drug prices high [STAT]
|
|
|
|
|
|
Our
patent system should reward only true inventions in science and
medicine. In the face of public health epidemics and out-of-control drug
pricing, we need a patent system that achieves a better balance between
the interests of corporations and the public.
|
|
|
|
|
|
|
6.6 Publications
|
|
|